Clinical Trial Update: An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol [Phase 4]

View source ↗

Summary

An extension study (Phase 4) of vemurafenib in participants with BRAF V600 mutation-positive malignancies who had prior vemurafenib exposure; status completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms | Phase 4 | Status: COMPLETED | Results posted: 2020-11-18